Financials
Financial year 2025
SOPHARMA from Tervuren, company number BE0476391546, closed financial year 2025 with a result of € 14.3 million after tax. For that financial year SOPHARMA recorded a gross margin of € 113,036 and equity of € 167.3 million. Compared with financial year 2024, the result moved from € 965,281 to € 14.3 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 30, 2026.
€ 167.3 million
▲ 213% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 14.3 million
▲ € 13.3 million vs 2024
Profit after tax over the fiscal year.
€ 836,424
▲ 208% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 336,941 paid out
2 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
1.5
▼ 1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 117,649
▼ 19% vs 2024
€ 78,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 13,096
▼ 32% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 2.1 million
▲ € 1.7 million vs 2024
€ 35,365 is repaid this year. At this pace the long-term loan is gone in ≈ 58 years.
€ 149,314
▲ 41% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 221,632
▼ 1% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 211,081 | € 430,273 | € 324,951 | € 113,036 | ▼ 65% |
| Profit after taxes | € 1,374,319 | € 1,115,077 | € 965,281 | € 14,296,439 | ▲ € 13.3 million |
| Equity | € 51,410,010 | € 52,525,087 | € 53,490,368 | € 167,332,901 | ▲ 213% |
| Total debts | € 997,688 | € 1,078,773 | € 812,553 | € 4,814,533 | ▲ € 4 million |
| Cash | € 290,280 | € 154,531 | € 271,914 | € 836,424 | ▲ 208% |
| Land & buildings | € 586,770 | € 2,414,783 | € 2,706,475 | € 2,609,281 | ▼ 4% |
| Retained profit | € 34,860,010 | € 35,975,087 | € 36,940,368 | € 114,536,219 | ▲ 210% |
| Dividend | € 0 | € 0 | € 0 | € 336,941 | |
| Bank debt | € 409,408 | € 375,402 | € 341,100 | € 2,056,422 | ▲ € 1.7 million |
| Balance sheet total | € 52,407,699 | € 53,603,860 | € 54,302,920 | € 172,147,434 | ▲ 217% |
| Employees (FTE) | 2.5 | 1.8 | 2.5 | 1.5 | ▼ 1 |
Key figures of SOPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to SOPHARMA?
What happened at SOPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Concellent stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 14.3 million (▲ € 13.3 million vs 2024). Source: NBB ↗
- Concellent became a director. NBB
- New establishment in Tervuren. KBO
- Start of the company according to the CBE. KBO
In short
From € 1.4 million profit in 2022 to € 14.3 million profit in 2025.
Paid € 536,547 in corporate taxes since 2022.
Best year ever: 2025, with € 14.3 million profit.
On average € 75,400 of value added per employee in 2025.
A new publication or filing at SOPHARMA? We notify you, reason included.
Follow SOPHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
It owns 50% of Concellent NV and 40.8% of Stichting Administratiekantoor MBS itself.
Directors
According to the 2025 annual accounts
Managing director · represented by Sofie Boone
Also active at: LOTUS BAKERIES, BEKINA, LEVEL NEXT
since 2026 · until 2031
Establishments
Establishment units
Physical locations of this company
Jezus Eiklaan 2A
3080 Tervuren
Jezus Eiklaan 2 A
3080 Tervuren
Active since 15 February 2002
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
CLOUDFLARENET - Cloudflare, Inc., US
DNS
Cloudflare DNS
Website info
Features
Security
Network
Details
- Company number
- 0476.391.546
- VAT number
- BE 0476.391.546
- Registered office
- Jezus Eiklaan 2A, 3080 Tervuren
- Names & denominations
- SOPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 20 December 2001
- Peppol
- Active · Active since 23 Oct 2025
- Contact
- apotheekboone.be [email protected]
- Activities · NACE
Apothekers
Detailhandel in farmaceutische producten
Detailhandel in cosmetica en toiletartikelen